Psychiatr. praxi. 2014;15(3):112-117

Diagnosis and pharmacotherapy of adult ADHD

doc.MUDr.Jiří Masopust, Ph.D., doc.MUDr.Pavel Mohr, Ph.D.2,3, doc.MUDr.Martin Anders, Ph.D.4, prof.MUDr.Radovan Přikryl, Ph.D.5
1 Psychiatrická klinika LF UK a FN Hradec Králové
2 Psychiatrické centrum Praha
3 3. LF UK Praha
4 Psychiatrická klinika 1. LF UK a VFN Praha
5 Psychiatrická klinika MU a FN Brno

Attention deficit and/or hyperactivity disorder (ADHD) is among the most common psychiatric disorders of childhood that persist into

adulthood in the majority of cases. Diagnosis of ADHD should be considered even if not diagnosed earlier during childhood; persistence

of symptoms and fuctional impairment are essential. Stimulants and atomoxetine are the drugs with the strongest evidence of efficacy

in therapy of adult ADHD. Atomoxetine is the only drug approved for treatment of adult ADHD in the Czech Republic. This paper summarizes

data on diagnosis and psychopharmacotherapy of adult ADHD.

Keywords: attention deficit and, or hyperactivity disorder (ADHD), atomoxetine, stimulants

Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masopust J, Mohr P, Anders M, Přikryl R. Diagnosis and pharmacotherapy of adult ADHD. Psychiatr. praxi. 2014;15(3):112-117.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009a; 29: 44-50. Go to original source... Go to PubMed...
    2. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009b; 26: 212-221. Go to original source... Go to PubMed...
    3. Adler L, Tanaka Y, Williams D, Trzepacz PT, Goto T, Allen AJ, Escobar R, Upadhyaya HP. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol 2014; 34: 461-466. Go to original source... Go to PubMed...
    4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washigton, DC, 2013. Go to original source...
    5. Antshel KM, Barkley R. Developmental and behavioral disorders grown up: attention deficit hyperactivity disorder. J Dev Behav Pediatr 2009; 30: 81-90. Go to original source... Go to PubMed...
    6. Asherson P, Chen W, Craddock B, Taylor E. Adult attentiom-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry 2007; 190: 4-5. Go to original source... Go to PubMed...
    7. Asherson P, Bushe C, Saylor K, Tanaka Y, Deberdt W, Upadhyaya H. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol. 2014 Jul 17. pii: 0269881114542453. [Epub ahead of print] Go to original source... Go to PubMed...
    8. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 59: 829-835. Go to original source... Go to PubMed...
    9. Buitelaar JK, Kan CC, Asherson P (eds.). ADHD in adults. Characterization, Diagnosis, and Treatment. Cambridge University Press, New York 2011: 314. Go to original source...
    10. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699-711. Go to original source... Go to PubMed...
    11. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190: 402-409. Go to original source... Go to PubMed...
    12. Garnock-Jones KP, Keating GM. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 2010; 24: 85-88. Go to original source... Go to PubMed...
    13. Heal DJ, Smith SL, Findling RL. ADHD: Current and Future Therapeutics. In.: C. Stanford and R. Tannock (eds.), Behavioral Neuroscience of Attention Deficit Hyperactivity Disorder and Its Treatment, Current Topics in Behavioral Neurosciences 9, Springer-Verlag Berlin Heidelberg 2011. Go to original source...
    14. Kessler RC, Lane M, Stang PE, Van Brunt DL. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med 2009; 39: 137-147. Go to original source... Go to PubMed...
    15. Klein RG, Mannuzza S. Comorbidity in adult attention-deficit hyperaktivity disorder. In: Retz W, Klein RG (eds.). Attention-deficit hyperaktivity disorder (ADHD) in adults. Key issues in mental health. Basel: Karger 2010; 126-143. Go to original source...
    16. Kooij JJS, Burger H, Boonstra AM, van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004; 34: 973-982. Go to original source... Go to PubMed...
    17. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010; 10: 67. Go to original source... Go to PubMed...
    18. Mannuzza S, Klein RG, Moulton JL 3rd.Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res 2008; 160: 237-246. Go to original source... Go to PubMed...
    19. Matte B, Rohde LA, Grevet EH. ADHD in adults: a koncept in evolution. ADHD Atten Def Hyp Disord 2012; 4: 53-62. Go to original source... Go to PubMed...
    20. Matte B, Anselmi L, Salum GA, Kieling C, Gonçalves H, Menezes A, Grevet EH, Rohde LA. ADHD in DSM5: a field trial in a large, representative sample of 18- to 19-year-old adults. Psychol Med 2014; Jun 23: 1-13. [Epub ahead of print]. Go to original source... Go to PubMed...
    21. McLean A, Dowson J, Toone B, Young S, Nazanis E, Robbins T, Sahakian B. Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder. Psychol Med 2004; 34: 681-692. Go to original source... Go to PubMed...
    22. Mohr P, Anders M, Přikryl R, Masopust J, Praško J, Hoschl C. Konsensus ČNPS o diagnostice a léčbě ADHD v dospělosti. Psychiatrie 2013; 17: 189-202.
    23. Paclt I (Ed.). Hyperkinetická porucha a poruchy chování. Grada, Praha 2007: 234.
    24. Ramos-Quiroga JA, Montoya A, Kutzelnigg A, Deberdt W, Sobanski E. Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness and treatment guidelines. Curr Med Res Opin 2013; 29: 1573. Go to original source... Go to PubMed...
    25. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attentiondeficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259: 120-129. Go to original source... Go to PubMed...
    26. Skirrow C, McLoughlin G, Kuntsi J, Asherson P. Behavioral, neurocognitive and treatment overlap between attention deficit/hyperactivity disorder and mood instability. Expert Rev Neurother 2009; 9: 489-503. Go to original source... Go to PubMed...
    27. Surman CBH, Biederman J, Spencer T, Miller CA, McDermott KM, Faraone SV. Understanding deficient emotional self-regulation in adults with attention deficit hyperaktivity disorder: a controlled study. ADHD Atten Def Hyp Disord 2013; 5: 273-281. Go to original source... Go to PubMed...
    28. Theiner P. ADHD od dětství do dospělosti. Psychiatr praxi 2012; 13: 148-150.
    29. Thomason C, Michelson D. Atomoxetine - treatment of attention deficit hyperactivity disorder: beyond stimulants. Drugs Today (Barc) 2004; 40: 465-473. Go to original source... Go to PubMed...
    30. Upadhyaya H, Ramos-Quiroga JA, Williams D, Tanaka Y, Lane JR, Escobar R, Trzepacz P, Camporeale A, Allen AJ. Maintenance of response after open label treatment with atomoxetine in adults with attention deficit hyperactivity disorder. Eur Neuropsychopharmacol 2012; 22(suppl 2): S427-S428. Go to original source...
    31. Upadhyaya HP, Desaiah D, Schuh KJ, Bymaster FP, Kallman MJ, Clarke DO, Durell TM, Trzepacz PT, Calligaro DO, Nisenbaum ES, Emmerson PJ, Schuh LM, Bickel WK, Allen AJ. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology 2013; 226: 189-200. Go to original source... Go to PubMed...
    32. Volkow ND, Swanson JM. Clinical practice: Adult attention deficit-hyperactivity disorder. N Engl J Med 2013; 369: 1935-1944. Go to original source... Go to PubMed...
    33. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR; Atomoxetine ADHD/SUD Study Group. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008, 96: 145-154. Go to original source... Go to PubMed...
    34. Wilens TE, Haight BR, Horrigan JP, Hudziak JJ, Rosenthal NE, Connor DF, Hampton KD, Richard NE, Modell JG: Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005; 57: 793-801. Go to original source... Go to PubMed...
    35. Young JL, Sarkis E, Qiao M, Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/ hyperactivity disorder: a 24-week, randomized, doubleblind, placebo controlled trial. Clin Neuropharmacol 2011; 34: 51-60. Go to original source... Go to PubMed...
    36. Young S, Moss D, Sedgwick O, Fridman M, Hodgkins P. A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychol Med. 2014 Apr 7: 1-12. [Epub ahead of print].

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.